Writing Process
Every article on DCAGuide.org begins with the primary literature. Daria Matej identifies the most relevant peer-reviewed studies, clinical trials, case reports, and systematic reviews for each topic before a word of content is written. Claims in DCAGuide articles are sourced directly from those primary references, not from secondary summaries or news coverage.
Once a draft is written, it is reviewed for medical accuracy, appropriate risk framing, balanced representation of the evidence base (including what is not yet known), and clarity for a general reader. Where evidence is preliminary or contested, that is stated explicitly. Where significant risks or contraindications exist — such as peripheral neuropathy risk with prolonged DCA use, or caution required in patients with existing liver disease — those are foregrounded, not buried.
Medical Review
All medically significant articles on this site are reviewed by a qualified physician before publication. The reviewer’s credentials and role are disclosed on each article page. For current medical reviewer information, see the Authors and Reviewers page.
Update Policy
Medical knowledge evolves. DCAGuide.org reviews its core condition pages — cancer, endometriosis, chronic fatigue syndrome, dosing, and safety — on an annual basis, or sooner when significant new studies are published. Each page carries a “last reviewed” date so readers know how current the information is.
Corrections
If you believe any information on this site is factually incorrect or misleading, please contact us using the details below. Errors are corrected promptly, with a note indicating the correction was made and when.
What This Site Is — and What It Is Not
DCAGuide.org is an educational resource. It is not a clinic, a prescribing service, or a substitute for qualified medical advice. Nothing on this site should be used to make treatment decisions without the involvement of a healthcare professional who knows the patient’s individual circumstances.
DCA is not approved by any regulatory agency for the treatment of cancer or other conditions beyond certain metabolic disorders. Its use in cancer, endometriosis, and chronic fatigue syndrome is off-label and experimental. The fact that promising research exists does not mean it is appropriate for every person, or that it is safe to use without professional guidance.
This site does not accept payment for supplier listings or editorial coverage. Our supplier overview pages describe available products and quality criteria to help readers ask better questions — they do not constitute endorsements or purchasing recommendations.
The site does not receive advertising revenue from DCA manufacturers or distributors, and it does not have financial arrangements with any clinic offering DCA therapy. These disclosures exist because, in a YMYL (Your Money or Your Life) topic area like experimental cancer therapy, transparency about potential conflicts of interest is a baseline requirement for reader trust.
The Broader Vision
The history of medicine is full of compounds and approaches that spent years or decades in the margins before the evidence reached critical mass. The reasons are rarely purely scientific: patent economics, publication bias, commercial incentives in drug development, and the sheer inertia of established treatment protocols all play a role.
DCA sits in an unusual position. It has accumulated more than forty years of safety data, a body of mechanistic research explaining how it targets the Warburg effect in cancer cells, a growing set of clinical observations from patient populations at centres like Medicor, and — critically — no commercial sponsor to fund the large Phase III trials that would give it the kind of regulatory standing that leads to mainstream adoption.
What that means, practically, is that clinicians working in metabolic oncology, integrative medicine, and supportive care need independent, honest, well-organized information about DCA — and so do the patients and families trying to make sense of their options. That is what DCAGuide.org is for.
The site’s ambition is not to advocate for DCA, but to reflect the evidence about it accurately, responsibly, and without commercial distortion — and to do so at a standard of medical rigor that clinicians can trust as much as patients can.
Community and Funding
DCAGuide.org has no institutional funding and no corporate backing. The site is sustained by small voluntary donations from individuals who have found it useful — a model that has kept it independent since 2017 and that reflects the community spirit in which it was originally built.
If you find value in this resource and would like to help it continue, you are welcome to contribute via the donation link. Funds go entirely toward hosting, maintenance, and the time required to keep content medically current.
Contact
For questions about content, corrections, media enquiries, or collaboration proposals:
Email: info@dcaguide.org
For urgent medical questions, please contact a qualified healthcare professional. DCAGuide.org cannot provide personalised medical advice.